Spero Therapeutics Inc (SPRO)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Spero Therapeutics Inc. The company’s shares closed on Friday at $8.57, close to its 52-week low of $7.80.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 26.0% and a 48.2% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Global Blood Therapeutics.
Spero Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $23.25, which is a 171.3% upside from current levels. In a report issued on November 5, Cantor Fitzgerald also maintained a Buy rating on the stock with a $27 price target.
Cowen & Co. analyst Boris Peaker maintained a Hold rating on Celldex today. The company’s shares closed on Friday at $0.36, close to its 52-week low of $0.30.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.0% and a 42.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Celldex with a $2.15 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.